Aclarion, Inc. (NASDAQ:ACON) stock is trading higher on Tuesday after the company announced it secured funding for its CLARITY trial of its diagnostic tool, Nociscan.
What To Know: The company has raised approximately $20 million in gross proceeds since the start of 2025, which will fully fund the clinical trial. The ...